Role of Interventional Cardiologists in Secondary Prevention of Acute Coronary Syndromes: Redefining Clinical Practice

By clicking the continue button above, I certify I have read the CME/MOC statements below.

Release date: September 15, 2018
Expiration date: September 15, 2019

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death and mortality in the United States, and elevated serum low-density lipoprotein cholesterol (LDL-C) is a widely-recognized risk factor. Because most initial presentations of symptoms of heart disease are referred to interventional cardiologists, these clinicians play a central role in managing patients with clinical ASCVD and preventing recurrence of major adverse cardiac events. Since hypercholesterolemia is a major driver of ASCVD, lipid-lowering therapies (mainly in combination with statins) are the primary treatment approach to lower LDL-C and reduce CVD risk.

The CME activity, The Role of Interventional Cardiologists in Secondary Prevention of Acute Coronary Syndromes: Redefining Clinical Practice, will help interventional cardiologists and other members of the cardiac care team ensure that ASCVD patients receive optimal lipid-lowering therapy to reduce the risk of recurrent events. Modules within the activity will allow participants to explore current guideline recommendations and clinical-trial results, review new and emerging treatment options, and discuss the benefits and limitations of those therapies.

Module 1: Residual CVD Risk in Patients with History of ACS
Module 2: Add-on Therapies to Enhance the Ability of Statins to Reduce LDL-C and Lower CVD Risk
Module 3: PCSK9 Inhibition: Clinical Data on Enhanced LDL-C Reduction and Reduced CVD Risk

 Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
 Executive Director of Interventional Cardiovascular Programs
 Brigham and Women's Hospital Heart and Vascular Center
 Professor of Medicine
 Harvard Medical School
 Boston, MA


Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women’s Hospital and a Senior Investigator in the TIMI Study Group.

After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology, while also serving as a Research Associate at Harvard Medical School. He received his medical doctorate from Cornell University and a Master’s in Public Health with a concentration in clinical effectiveness from Harvard University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and Associate Professor of Medicine.

Dr. Bhatt’s research interests include acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored more than 1,100 publications and is listed as a Thomson Reuters Highly Cited Researcher. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and Atherothrombosis in Clinical Practice and served as the international Principal Investigator for the CHARISMA and CRESCENDO trials. He has been listed in Best Doctors in America from 2005 to 2018. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017 and the ACC’s Distinguished Mentor Award in 2018. He is the Editor of the peer-reviewed Journal of Invasive Cardiology, Chief Medical Editor of Cardiology Today’s Intervention for healthcare professionals, and Editor-in-Chief of the Harvard Heart Letter for patients.

 James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA
 Lipidology and Cardiovascular Disease Prevention
 Clinical Assistant Professor of Medicine
 NYU Medical School and NYU Center for CV Prevention
 Director, Bellevue Hospital Lipid Clinic
 Past-President, National Lipid Association
 New York, NY

James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic.

Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology, a Fellow of the National Lipid Association, and a Past-President of the National Lipid Association. He is a board member of the National Lipid Association and the Foundation of the National Lipid Association, as well as President-Elect of the American Board of Clinical Lipidology.

Dr. Underberg’s clinical interests focus on the management of patients with lipids and lipoprotein disorders, hypertension management, and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology. He sees patients both at Bellevue Hospital and in a university-based private-practice setting.

This activity is intended for cardiologists, interventional cardiologists, lipidologists, and other healthcare professionals who manage patients with atherosclerotic cardiovascular disease (ASCVD).

At the conclusion of this activity, participants should be able to demonstrate the ability to: 

  • Identify residual CVD risk in high-risk patients and address additional CVD risk elements as appropriate
  • Differentiate the clinical properties of new and emerging pharmacologic approaches to reduce LDL-C and lower CVD risk
  • Analyze the potential strengths and weaknesses of new approaches to reduce CVD risk with new LDL-C -lowering agents in combination with statins

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this online activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions regarding CME credit, the post-test, or evaluation, please email

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and other professor organizations, as applicable, stating those activities where continuing medical education credits are awarded must be balanced, independent, objective, and scientifically rigorous. 

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

Program Faculty Disclosures

The program faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC: Grant/Research Support: Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA: Consultant/Independent Contractor: Amarin, Amgen; Grant/Research Support: Aegerion, Pfizer; Honoraria/Advisory Board: Aegerion, Akcea, Alexion, Amarin, Amgen, Merck, Regeneron, Sanofi; Speaker's Bureau: Aegerion, Akcea, Alexion, Amarin, Amgen, Merck, Regeneron, Sanofi

Non-faculty Content Contributors Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Blair St. Amand; Lindsay Scott, PT, DPT, ATC; Ashley Marostica, RN, MSN, CCM: Nothing to disclose

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Jointly provided by Potomac Center for Medical Education and Rockpointe


This program is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.